On October 20, 2021 NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell therapies, reported that a Phase I study of SNK01 monotherapy in refractory cancers has been accepted for presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting being held virtually November 10 – 13, 2021 (Press release, NKMax America, OCT 20, 2021, View Source [SID1234591589]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation

Title: Phase I study of escalating doses of ex vivo expanded, autologous natural killer cells in patients with pathologically confirmed cancer refractory to conventional therapy.

Poster #: P152

Presentation Date and Time: November 12, 2021 from 2:30 pm – 3:15 pm ET

More information on the 2021 CTOS Annual Meeting and related posters sessions can be found at the following link View Source